Lifecore's $6.28 Sale Heads To Shareholders With About 27% Of Votes Committed
Common holders would receive cash and a milestone-payment right, but the buyer has no obligation to achieve those milestones.
Lifecore Biomedical, which develops and manufactures sterile injectable drugs for other companies, set a December 23 vote Friday on its $6.28-per-share sale, with about 27% of voting power committed to approval. Its definitive merger proxy described the proposed payout as cash plus one contingent value right per common share from Lifecore, the buyer affiliated with Webster Equity Partners.
Cash Premium, Conditional Extra Payments
The board unanimously recommended the deal. The $6.28 cash payment represents about a 50% premium to LFCR's closing price on September 25, 2026.
The contingent value rights give holders a claim on possible milestone payments. Performance payments could reach an aggregate $160 million before litigation adjustments, but the buyer has no contractual duty to achieve the milestones.
Craig-Hallum, the transaction committee's financial adviser, judged the common-share payout financially fair under its assumptions and limitations. It assigned no value to the contingent rights in reaching that conclusion.
Preferred holders would receive cash based on their contractual conversion amount, plus a right for each common share into which their holdings could convert. As of September 27, 2026, that cash amount equated to $6.53 per common share.
Redemption Pressure Behind The Sale
Preferred shareholders demanded redemption in June, requiring approximately $52.1 million. Lifecore had $38.1 million of liquidity at March 31, placing the negotiations against a strained capital structure.
The company signed the merger agreement on September 27, 2026. A subsequent search contacted 110 potential counterparties and ended October 28 without an acquisition proposal. The federal antitrust waiting period received early termination on November 4.
Based in Chaska, Minnesota, Lifecore fills injectable drugs and medical-device products into syringes, vials and cartridges, including thick formulations. It also produces pharmaceutical-grade hyaluronic acid for customers' injectables, including ophthalmic and orthopedic uses.
Committed Votes Fall Short Of Majority
Stockholders associated with Wynnefield Capital and Legion Partners, the investor groups that signed support agreements, committed holdings representing about 27% of combined voting power as of the record date.
Approval requires a majority of all outstanding voting power across common and preferred shares. Preferred holders vote according to the common shares their holdings could convert into; abstentions and shares left unvoted count the same as opposition.
If the deal closes, Lifecore Biomedical would become the buyer's wholly owned subsidiary, and its common shares would leave Nasdaq. If it fails, holders retain their shares in an independent public company and receive no merger payment.
The buyer owes a $16.2 million termination fee for specified breaches or failure to close. Lifecore expects completion at the end of the fourth quarter of 2026, contingent on shareholder approval and remaining requirements.
The December 23 vote will determine whether holders approve the cash payout and exchange their ownership for contingent payment rights.
Sources
- DEFM14A — LIFECORE BIOMEDICAL, INC. \DE\ re: LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) — SEC EDGAR
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of — globenewswire.com
- Halper Sadeh LLC is Investigating Whether RXO, PTC, LFCR — globenewswire.com